Company intelligence

Souffle Therapeutics

BiotechSee connections →Compare with Anthropic
Last verified Oct 13, 2026

Key Metrics

Total funding
$330M+
As of Oct 13, 2026FinancialContent

Recent changes

  1. Oct 13, 2026Raised $135M Series B FinancialContent
  2. Oct 13, 2026First reported total funding: $330M+ FinancialContent
  3. Oct 13, 2026New investor: Fidelity Investments FinancialContent
  4. Oct 13, 2026New investor: Temasek FinancialContent
  5. Oct 13, 2026New investor: Polaris Partners FinancialContent
Earlier changes (6)
  1. Oct 13, 2026New investor: Vida Ventures FinancialContent
  2. Oct 13, 2026New investor: Janus Henderson Investors FinancialContent
  3. Oct 13, 2026New investor: Bessemer Venture Partners FinancialContent
  4. Oct 13, 2026New investor: Leaps by Bayer FinancialContent
  5. Oct 13, 2026New investor: ARCH Venture Partners FinancialContent
  6. Oct 13, 2026Souffle Therapeutics Raises $135M For RNA Therapies Pulse story

Funding History

1 event · sources dated per row
DateEventAmountValuationInvestorsSource
Oct 13, 2026Series B$135M—
Fidelity InvestmentsunverifiedARCH Venture PartnersunverifiedBessemer Venture PartnersunverifiedJanus Henderson InvestorsunverifiedLeaps by BayerunverifiedPolaris PartnersunverifiedTemasekunverifiedVida VenturesunverifiedJuvia GroupTCG Crossover ManagementBB BiotechBalyasny Asset Management+5 more
FinancialContent

Investors

ARCH Venture PartnersBessemer Venture PartnersFidelity InvestmentsJanus Henderson InvestorsLeaps by BayerPolaris PartnersTemasekVida Ventures

Latest Pulse

  1. Souffle Therapeutics Raises $135M For RNA TherapiesSouffle Therapeutics closed an oversubscribed $135 million Series B led by Juvia Group on Oct. 13 to push its RNA-delivery platform's first three programs toward the clinic.→

Coverage Timeline

newest first
  1. Oct 13, 2026FUNDINGSouffle Therapeutics Raises $135M For RNA Therapies$135M Series B→

All Coverage

FUNDING

Souffle Therapeutics Raises $135M For RNA Therapies

Illustration for: Souffle Therapeutics Raises $135M For RNA Therapies
FUNDING$135M Series B

Souffle Therapeutics Raises $135M For RNA Therapies

Souffle Therapeutics closed an oversubscribed $135 million Series B led by Juvia Group on Oct. 13 to push its RNA-delivery platform's first three programs toward the clinic.

DEEP DIVE

Related Companies

Shared investors
Encoded TherapeuticsAnthropicEpicrispr BiotechnologiesTriveni Bio

Souffle Therapeutics FAQ

How much has Souffle Therapeutics raised?

Souffle Therapeutics has raised $330M+ in total funding (As of Oct 13, 2026, FinancialContent).

Who are Souffle Therapeutics's investors?

Souffle Therapeutics's investors include ARCH Venture Partners, Bessemer Venture Partners, Fidelity Investments, Janus Henderson Investors, Leaps by Bayer, and 3 more (As of Oct 13, 2026).

Sources & methodologyshow
Where these figures come from

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction